Drug Profile
Research programme: monoclonal antibody therapeutics - Arrowhead Pharmaceuticals/Juno Therapeutics
Alternative Names: Antibody cancer therapeutics - Arrowhead Pharmaceuticals/Juno Therapeutics; Human antibody therapeutic candidates - Arrowhead Pharmaceuticals/Juno TherapeuticsLatest Information Update: 09 Mar 2018
Price :
$50
*
At a glance
- Originator Mercator Therapeutics; X-BODY BioSciences
- Developer Alvos Therapeutics; Juno Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 06 Mar 2018 Juno Therapeutics has been acquired by Celgene
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 02 Jun 2015 X-BODY BioSciences has been acquired by Juno Therapeutics